미토콘드리아 기능 조절제로서의 벤즈이미다졸 유도체
    233.
    发明公开
    미토콘드리아 기능 조절제로서의 벤즈이미다졸 유도체 有权
    苯并咪唑衍生物作为麻醉功能调节剂

    公开(公告)号:KR1020140050802A

    公开(公告)日:2014-04-30

    申请号:KR1020120117057

    申请日:2012-10-22

    Abstract: The present invention relates to a benzimidazole derivative which has pharmaceutical activity as a neuroprotective agent by modulating mitochondrial functions and a pharmaceutical composition comprising the same as an active ingredient. The benzimidazole derivative or a pharmaceutically acceptable salt thereof, according to the present invention, has an excellent activity as a neuroprotective agent affecting mitochondria, thereby can be used as a medicine for diseases such as Alzheimer′s disease, Parkinson′s disease, Huntington′s disease, ischemic brain disease, diabetes, and schizophrenia.

    Abstract translation: 本发明涉及通过调节线粒体功能而具有作为神经保护剂的药学活性的苯并咪唑衍生物和包含其作为活性成分的药物组合物。 根据本发明的苯并咪唑衍生物或其药学上可接受的盐作为影响线粒体的神经保护剂具有优异的活性,因此可以用作诸如阿尔茨海默氏病,帕金森病,亨廷顿病, 缺血性脑病,糖尿病和精神分裂症。

    T형 칼슘 채널 저해작용을 가지는 신규 1-(4-할로페닐 옥소 또는 싸이오)-3-(4-치환피페라진-1-일)프로판-2올 유도체 또는 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 하는 약학적 조성물
    237.
    发明公开
    T형 칼슘 채널 저해작용을 가지는 신규 1-(4-할로페닐 옥소 또는 싸이오)-3-(4-치환피페라진-1-일)프로판-2올 유도체 또는 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 하는 약학적 조성물 无效
    新型1-(4-戊烯基氧基或硫代)-3-(4-取代的哌嗪-1-基)丙烷-2-醇衍生物,其具有T型钙通道抑制活性或药物可接受的盐,其制备方法和药物组合物包含 同样作为活跃成分

    公开(公告)号:KR1020120066699A

    公开(公告)日:2012-06-25

    申请号:KR1020100093304

    申请日:2010-09-27

    Abstract: PURPOSE: A pharmaceutical composition containing a novel 1-(4-halophenyl oxo or thio)-3-(4-substituted piperazine-1-yl)propane-2-ol derivative is provided to effectively suppress T type calcium channel activation and to prevent or treat hypertension, cancer, epilepsy, and neurogenic pain. CONSTITUTION: A novel 1-(4-halophenyl oxo or thio)-3-(4-substituted piperazine-1-yl)propan-2-ol derivative is denoted by chemical formula 1. A method for preparing the compound of chemical formula 1 comprises: a step of reacting a compound of chemical formula 2 with chiral epichlorohydrin under the presence of a base and solvent to prepare an epoxy compound of chemical formula 3; and a step of reacting the epoxy compound of chemical formula 3 with piperazine derivative of chemical formula 4. The base is potassium carbonate, sodium carbonate or pyridine. A pharmaceutical composition for preventing or treating diseases caused by overactivation of T type calcium channel contains the derivative or pharmaceutically acceptable salt thereof as an active ingredient.

    Abstract translation: 目的:提供含有新型1-(4-卤代苯基氧代或硫代)-3-(4-取代哌嗪-1-基)丙-2-醇衍生物的药物组合物,以有效抑制T型钙通道激活和预防 或治疗高血压,癌症,癫痫和神经源性疼痛。 构成:化学式1表示新的1-(4-卤代苯基氧代或硫代)-3-(4-取代哌嗪-1-基)丙-2-醇衍生物。一种制备化学式1化合物的方法 包括:在碱和溶剂的存在下使化学式2的化合物与手性表氯醇反应以制备化学式3的环氧化合物的步骤; 和使化学式3的环氧化合物与化学式4的哌嗪衍生物反应的步骤。碱是碳酸钾,碳酸钠或吡啶。 用于预防或治疗由T型钙通道过度活化引起的疾病的药物组合物含有其衍生物或药学上可接受的盐作为活性成分。

    항암활성을 지닌 카르보아졸계 화합물
    239.
    发明公开
    항암활성을 지닌 카르보아졸계 화합물 有权
    具有抗癌活性的新型咔唑类化合物

    公开(公告)号:KR1020120056684A

    公开(公告)日:2012-06-04

    申请号:KR1020100118341

    申请日:2010-11-25

    Abstract: PURPOSE: A carboazole-based compounds with an anticancer activity and a method for preparing the same are provided to prevent and treat cancer. CONSTITUTION: A carboazole-based compound with an anticancer activity is denoted by chemical formula 1. A pharmaceutical composition for anticancer contains the carboazole-based compounds of chemical formula 1. A method for preparing the carboazole-based compounds comprises: a step of reacting amidation of heterocyclic compounds of chemical formula III with 4-haloazole compounds of chemical formula IV to prepare a 4-halocaboazole-based compound of chemical formula V; and a step of performing Suzuki coupling of the compound of chemical formula V with a boronic acid compound of chemical formula VI.

    Abstract translation: 目的:提供具有抗癌活性的基于咔唑的化合物及其制备方法,以预防和治疗癌症。 构成:具有抗癌活性的基于唑的化合物由化学式1表示。用于抗癌的药物组合物含有化学式1的咔唑类化合物。一种制备该类咔唑类化合物的方法包括:使酰胺化反应 的化学式III的4-卤唑化合物的化学式III的杂环化合物,以制备化学式V的4-卤代咔唑类化合物; 以及化学式V化合物与化学式VI的硼酸化合物的Suzuki偶联的步骤。

    GSK-3 억제활성을 보이는 1H-인다졸 화합물
    240.
    发明公开
    GSK-3 억제활성을 보이는 1H-인다졸 화합물 有权
    具有GSK-3抑制活性的1H-吲唑化合物

    公开(公告)号:KR1020120038033A

    公开(公告)日:2012-04-23

    申请号:KR1020100097910

    申请日:2010-10-07

    Abstract: PURPOSE: A 1H-indazole compound with GSK3 inhibition and pharmaceutically acceptable salt thereof are provided to be used as a therapeutic agent for treating diseases caused by GSK-3 activation. CONSTITUTION: A 1H-indazole compounds is denoted by chemical formula 1. A method for preparing the compound comprises: a step of performing amidation of 3-amino-1H-indazole compounds of chemical formula 2 and a substituted carboxylic acid compound of chemical formula 3 under the presence of pyridine base and 1-ethyl-3-(3'-dimethyl aminopropyl)carbodiimide hydrochloride(EDCI).

    Abstract translation: 目的:提供具有GSK3抑制的1H-吲唑化合物及其药学上可接受的盐作为治疗由GSK-3激活引起的疾病的治疗剂。 构成:1H-吲唑化合物由化学式1表示。一种制备化合物的方法包括:进行化学式2的3-氨基-1H-吲唑化合物和化学式3的取代的羧酸化合物的酰胺化步骤 在吡啶碱和1-乙基-3-(3'-二甲基氨基丙基)碳二亚胺盐酸盐(EDCI)的存在下。

Patent Agency Ranking